Trevena (NASDAQ: TRVN): A Biotech Low Float Runner : compare

Trevena (NASDAQ: TRVN) announced that its partner, Jiangsu Nhwa, has received approval from China's National Medical Products Administration (NMPA) for its opioid pain medication, Olinvyk.

Related Keywords

China , Jiangsu Nhwa , Carrie Bourdow , Healthcare Fund , Exchange Commission , China National Medical Products Administration , National Medical Products Administration , R Bridge Healthcare Fund , R Bridge Financing , Inside Scoop , Right Now , Stock Halt Alerts , Dell Thomas Investing , Featured , Trvn ,